Figure 4
Figure 4. ATRA plus sorafenib reduces long-term proliferative potential of FLT3/ITD+ cells. (A) CFU counts after 7 to 10 days’ plating of 5 × 102 Molm14, MV4-11, THP-1, or NB4 cells treated in triplicate with sorafenib (Sor, 20 nM) and/or ATRA (100 nM) for 48 hours. (B) CFU counts after 7 days’ plating of 1 × 104 FLT3/ITD primary patient cells treated with sorafenib (20 nM) and/or ATRA (100 nM). Data indicate average colony number ± SD, and are representative of 3 independent experiments (**P < .01, ***P < .001).

ATRA plus sorafenib reduces long-term proliferative potential of FLT3/ITD+ cells. (A) CFU counts after 7 to 10 days’ plating of 5 × 102 Molm14, MV4-11, THP-1, or NB4 cells treated in triplicate with sorafenib (Sor, 20 nM) and/or ATRA (100 nM) for 48 hours. (B) CFU counts after 7 days’ plating of 1 × 104 FLT3/ITD primary patient cells treated with sorafenib (20 nM) and/or ATRA (100 nM). Data indicate average colony number ± SD, and are representative of 3 independent experiments (**P < .01, ***P < .001).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal